SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Harpoon Therapeutics, Inc. (HARP) .
Criteria proven by this page:
- VALUE (100/100, Pass) — analyst target implies upside (+2942.2%).
- Analyst consensus target $700.00 (+2942.2% upside) — significant upside potential according to Wall Street analysts.
Overall SharesGrow Score: 46/100 with 2/7 criteria passed.
SharesGrow 7-Criteria Score
✓
VALUE
100/100
Price-to-Earnings & upside
Proven by this page
✗
HEALTH
25/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — HARP
Valuation Multiples
P/E (TTM)0.0
Forward P/EN/A
PEG RatioN/A
Forward PEGN/A
P/B Ratio0.00
P/S Ratio2.39
EV/EBITDA0.0
Per Share Data
EPS (TTM)$-20.24
Book Value / Share$0.00
Revenue / Share$9.62
FCF / Share$0.00
Yields & Fair Value
Earnings YieldN/A
Dividend Yield0.00%
Analyst Target$700.00 (+2942.2%)
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2016 |
$-1.21 |
$0.00 |
$-11.41M |
- |
| 2017 |
$-17.81 |
$708K |
$-16.83M |
-2377.1% |
| 2018 |
$-11.45 |
$4.75M |
$-27.37M |
-576.1% |
| 2019 |
$-23.91 |
$5.78M |
$-52M |
-900.1% |
| 2020 |
$-18.52 |
$17.44M |
$-46.38M |
-265.9% |
| 2021 |
$-51.57 |
$23.65M |
$-166.44M |
-703.6% |
| 2022 |
$-20.24 |
$31.92M |
$-67.14M |
-210.4% |
